Skip to main content

Home/ Nutrition/ Group items tagged LDL

Rss Feed Group items tagged

Matti Narkia

MedWire News - Lipidology - High serum selenium associated with elevated LDL and total ... - 3 views

  •  
    "High serum selenium associated with elevated LDL and total cholesterol
    By Helen Albert
    21 January 2010
    Atherosclerosis 2009; Advance online publication

    MedWire News: High levels of serum selenium are associated with elevated total and low-density lipoprotein (LDL) cholesterol, report US researchers.

    The results add weight to those of a previous UK study, reported by MedWire News, that reported an association between high plasma selenium and an adverse lipid profile.

    Eliseo Guallar (Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland) and colleagues carried out a cross-sectional analysis of 1159 individuals aged 56.8 years on average who participated in the National Health and Nutrition Examination Survey (NHANES) 2003-2004."
Matti Narkia

Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adipo... - 0 views

  •  
    Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans.
    Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA, Graham JL, Hatcher B, Cox CL, Dyachenko A, Zhang W, McGahan JP, Seibert A, Krauss RM, Chiu S, Schaefer EJ, Ai M, Otokozawa S, Nakajima K, Nakano T, Beysen C, Hellerstein MK, Berglund L, Havel PJ.
    J Clin Invest. 2009 May;119(5):1322-34. Epub 2009 Apr 20.
    PMID: 19381015
    doi: 10.1172/JCI37385.

    Studies in animals have documented that, compared with glucose, dietary fructose induces dyslipidemia and insulin resistance. To assess the relative effects of these dietary sugars during sustained consumption in humans, overweight and obese subjects consumed glucose- or fructose-sweetened beverages providing 25% of energy requirements for 10 weeks. Although both groups exhibited similar weight gain during the intervention, visceral adipose volume was significantly increased only in subjects consuming fructose. Fasting plasma triglyceride concentrations increased by approximately 10% during 10 weeks of glucose consumption but not after fructose consumption. In contrast, hepatic de novo lipogenesis (DNL) and the 23-hour postprandial triglyceride AUC were increased specifically during fructose consumption. Similarly, markers of altered lipid metabolism and lipoprotein remodeling, including fasting apoB, LDL, small dense LDL, oxidized LDL, and postprandial concentrations of remnant-like particle-triglyceride and -cholesterol significantly increased during fructose but not glucose consumption. In addition, fasting plasma glucose and insulin levels increased and insulin sensitivity decreased in subjects consuming fructose but not in those consuming glucose. These data suggest that dietary fructose specifically increases DNL, promotes dyslipidemia, decreases insulin sensitivity, and increases visceral adiposity in overweight/obese adults.
Matti Narkia

NEJM -- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reacti... - 0 views

  •  
    Conclusions In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events. \n\nRosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.\nRidker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group.\nN Engl J Med. 2008 Nov 20;359(21):2195-207. Epub 2008 Nov 9.\nPMID: 18997196
Matti Narkia

JUPITER: Primary-prevention statin therapy in women cuts cardiovascular risk in half - ... - 0 views

  •  
    "November 25, 2009 | Michael O'Riordan

    Orlando, FL - Treating healthy women with low LDL cholesterol but elevated high-sensitivity C-reactive protein (hsCRP) levels with rosuvastatin (Crestor, AstraZeneca) cuts their risk of cardiovascular events in half, according to a new analysis of Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER).

    The reduction in risk is consistent with the reduction observed in the overall trial, and with the 42% benefit observed in men.
Matti Narkia

JUPITER: Low LDL and low CRP best for reducing events in primary prevention - theheart.org - 0 views

  •  
    "March 29, 2009 | Michael O'Riordan

    Orlando, FL - Reducing LDL cholesterol and high-sensitivity C-reactive protein (hs-CRP) in primary-prevention patients treated with rosuvastatin (Crestor, AstraZeneca) results in better event-free survival than when neither of these targets are achieved or when LDL cholesterol alone is reduced, a new analysis shows [1].

    Presenting the results of the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) study during an afternoon press conference at the American College of Cardiology 2009 Scientific Sessions, investigators say that initial interventions for low-risk primary-prevention patients remains lifestyle and dietary modifications, but for those choosing drug therapy, "reductions in both LDL cholesterol and hs-CRP are indicators of the success of treatment with statin therapy.""
Matti Narkia

Clinical Implications of JUPITER (Justification for the Use of statins in Prevention: a... - 0 views

  •  
    Clinical Implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. Population
    Insights From the ARIC (Atherosclerosis Risk in Communities) Study
    Yang EY et al.
    J Am Coll Cardiol, 2009; 54:2388-2395,
    doi:10.1016/j.jacc.2009.10.006

    Conclusions: ARIC participants with elevated hs-CRP and low LDL-C had a CVD event rate of 1.57% per year over 6.9 years, similar to the CVD event rate noted in the JUPITER study placebo group (1.36% per year over 1.9 years). The association of hs-CRP ≥2.0 mg/l with increased CVD risk and mortality regardless of LDL-C provides us a simple method of using age and hs-CRP level for identifying higher risk individuals. (Atherosclerosis Risk in Communities study; NCT00005131)
Matti Narkia

Patients With High CRP And Normal LDL Have Long-Term Risk For Heart Disease, Stroke And... - 0 views

  •  
    "New research shows a long-term benefit in screening people for CRP, a marker for inflammation, even if they have normal levels of bad cholesterol, because of increased long-term risk for heart attack, stroke and death.

    These findings, which will be published online today in the Journal of the American College of Cardiology (JACC), demonstrate that a very simple screening, age plus CRP, can identify individuals who may benefit from statin therapy.

    "This study builds on results from the landmark JUPITER trial, which showed that statins can prevent heart disease in people with normal LDL-c, or bad cholesterol, and an increased level of CRP," said Dr. Christie Ballantyne, director of the Center for Cardiovascular Disease Prevention at the Methodist DeBakey Heart & Vascular Center and last author on the study. "We have demonstrated that the cardiovascular disease event rates persist over time, validating that the risks identified in the JUPITER trial persist for nearly seven year"
Matti Narkia

NEJM -- Extended-Release Niacin or Ezetimibe and Carotid Intima-Media Thickness - 0 views

  •  
    Extended-release niacin or ezetimibe and carotid intima-media thickness.
    Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, Weissman NJ, Turco M.
    N Engl J Med. 2009 Nov 26;361(22):2113-22. Epub 2009 Nov 15.
    PMID: 19915217

    Conclusions This comparative-effectiveness trial shows that the use of extended-release niacin causes a significant regression of carotid intima-media thickness when combined with a statin and that niacin is superior to ezetimibe. (ClinicalTrials.gov number, NCT00397657 [ClinicalTrials.gov] .
Matti Narkia

Cardiovascular disease risk of dietary stearic acid compared with trans, other saturate... - 0 views

  •  
    Cardiovascular disease risk of dietary stearic acid compared with trans, other saturated, and unsaturated fatty acids: a systematic review1,3.
    Hunter JE, Zhang J, Kris-Etherton PM.
    Am J Clin Nutr. 2009 Nov 25. [Epub ahead of print]
    PMID: 19939984
    doi:10.3945/ajcn.2009.27661

    Conclusions: TFA intake should be reduced as much as possible because of its adverse effects on lipids and lipoproteins. The replacement of TFA with STA compared with other saturated fatty acids in foods that require solid fats beneficially affects LDL cholesterol, the primary target for CVD risk reduction; unsaturated fats are preferred for liquid fat applications. Research is needed to evaluate the effects of STA on emerging CVD risk markers such as fibrinogen and to understand the responses in different populations.
Matti Narkia

Berberine - a novel approach to cholesterol lowering; Expert Opinion on Investigational... - 0 views

  •  
    Berberine--a novel approach to cholesterol lowering.
    Doggrell SA.
    Expert Opin Investig Drugs. 2005 May;14(5):683-5.
    PMID: 15926873
Matti Narkia

Beneficial effects of virgin coconut oil on lipid parameters and in vitro LDL oxidation... - 0 views

  •  
    Beneficial effects of virgin coconut oil on lipid parameters and in vitro LDL oxidation.
    Nevin KG, Rajamohan T.
    Clin Biochem. 2004 Sep;37(9):830-5.
    PMID: 15329324
    doi:10.1016/j.clinbiochem.2004.04.010

    Conclusion: The results demonstrated the potential beneficiary effect of virgin coconut oil in lowering lipid levels in serum and tissues and LDL oxidation by physiological oxidants. This property of VCO may be attributed to the biologically active polyphenol components present in the oil
Matti Narkia

The Latest Studies on Coconut Oil - westonaprice.org - 0 views

  •  
    "One of the very useful oils in the food supply comes from the coconut. Coconut oil has suffered from unjust criticism for more than 30 years in the United States because some of the governmental and food oil organizations, as well as consumer activist organizations such as Center for Science in the Public Interest (CSPI), have claimed that coconut oil as a "saturated fat" is shown to be atherogenic. This is not true.

    There is a variety of supportive research published in 2003, 2004, and 2005, which shows the importance of coconut oil. Also, information on coconut oil is currently coming into the research literature from numerous countries, including India, Norway, Iran and the United States.

    The following are some of the most recent studies showing the benefits of coconut oil. These studies contradict claims that coconut oil contributes to heart disease and also support earlier research showing an antimicrobial role for the fatty acids in this traditional fat."
Matti Narkia

Effect of soy protein varying in isoflavone content on serum lipids in healthy young me... - 0 views

  •  
    Effect of soy protein varying in isoflavone content on serum lipids in healthy young men.
    McVeigh BL, Dillingham BL, Lampe JW, Duncan AM.
    Am J Clin Nutr. 2006 Feb;83(2):244-51.
    PMID: 16469981

    Conclusion: Soy protein, regardless of isoflavone content, modulates serum lipid ratios in a direction beneficial for cardiovascular disease risk in healthy young men.
Matti Narkia

Animal Pharm: 'Death Band' = sdLDL on Lipoprotein Subfractionation - 0 views

  •  
    Subfractionation of Lipoproteins 101

    Let's review some subfractionation techniques. On the market 3 main methods exist. They all work. Dr. Davis highly prefers NMR for its subtleties, scope, and particle counts. Superko and Krauss are affiliated with Berkeley HeartLab which uses GGE (BHL). Density gradient ultracentrifugation is very popular among our members (VAP-II and VAP). Recently, Krauss appears to be introducing a new technology based on ion-mobility.

    Basically, the denser the particle, the faster and more mobile the particle moves through a gel (GGE). The denser the particle, the smaller the diameter (Angstroms or nanometers) as determined via electromagnetic resonance (NMR) or absorbance via density ultracentrifugation (VAP, which are indirectly compared to known sizes).
Matti Narkia

The Heart Scan Blog: Small LDL: Perfect index of carbohydrate intake - 0 views

  •  
    "Measuring the number of small LDL particles is the best index of carbohydrate intake I know of, better than even blood sugar and triglycerides.

    In other words, increase carbohydrate intake and small LDL particles increase. Decrease carbohydrates and small LDL particles decrease.

    Why?

    Carbohydrates increase small LDL via a multistep process:

    First step: Increased fatty acid and apoprotein B production in the liver, which leads to increased VLDL production. (Apoprotein B is the principal protein of VLDL and LDL)

    Second step: Greater VLDL availability causes triglyceride-rich VLDL to interact with other particles, namely LDL and HDL, enriching them in triglycerides (via the action of cholesteryl-ester transfer protein, or CETP). Much VLDL is converted to LDL.

    Third step: Triglyceride-rich LDL is "remodeled" by enzymes like hepatic lipase, which create small LDL"
Matti Narkia

Berberine is a novel cholesterol-lowering drug working through a unique mechanism disti... - 0 views

  •  
    Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins.
    Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S, Wu J, Wang Y, Li Z, Liu J, Jiang JD.
    Nat Med. 2004 Dec;10(12):1344-51. Epub 2004 Nov 7.
    PMID: 15531889
    doi:10.1038/nm1135

    We identify berberine (BBR), a compound isolated from a Chinese herb, as a new cholesterol-lowering drug. Oral administration of BBR in 32 hypercholesterolemic patients for 3 months reduced serum cholesterol by 29%, triglycerides by 35% and LDL-cholesterol by 25%. Treatment of hyperlipidemic hamsters with BBR reduced serum cholesterol by 40% and LDL-cholesterol by 42%, with a 3.5-fold increase in hepatic LDLR mRNA and a 2.6-fold increase in hepatic LDLR protein. Using human hepatoma cells, we show that BBR upregulates LDLR expression independent of sterol regulatory element binding proteins, but dependent on ERK activation. BBR elevates LDLR expression through a post-transcriptional mechanism that stabilizes the mRNA. Using a heterologous system with luciferase as a reporter, we further identify the 5' proximal section of the LDLR mRNA 3' untranslated region responsible for the regulatory effect of BBR. These findings show BBR as a new hypolipidemic drug with a mechanism of action different from that of statin drugs.
Matti Narkia

Treatment of Type 2 Diabetes and Dyslipidemia with the Natural Plant Alkaloid Berberine... - 0 views

  •  
    Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine.
    Zhang Y, Li X, Zou D, Liu W, Yang J, Zhu N, Huo L, Wang M, Hong J, Wu P, Ren G, Ning G.
    J Clin Endocrinol Metab. 2008 Jul;93(7):2559-65. Epub 2008 Apr 8.
    PMID: 18397984
    doi:10.1210/jc.2007-2404

    Conclusions: Berberine is effective and safe in the treatment of type 2 diabetes and dyslipidemia.
Matti Narkia

Opposing effects of cis-9,trans-11 and trans-10,cis-12 conjugated linoleic acid on bloo... - 0 views

  •  
    Opposing effects of cis-9,trans-11 and trans-10,cis-12 conjugated linoleic acid on blood lipids in healthy humans.
    Tricon S, Burdge GC, Kew S, Banerjee T, Russell JJ, Jones EL, Grimble RF, Williams CM, Yaqoob P, Calder PC.
    Am J Clin Nutr. 2004 Sep;80(3):614-20.
    PMID: 15321800

    Conclusion: Divergent effects of cis-9,trans-11 CLA and trans-10,cis-12 CLA appear on the blood lipid profile in healthy humans: trans-10,cis-12 CLA increases LDL:HDL cholesterol and total:HDL cholesterol, whereas cis-9,trans-11 CLA decreases them.
Matti Narkia

Effects of dairy products naturally enriched with cis-9,trans-11 conjugated linoleic ac... - 0 views

  •  
    Effects of dairy products naturally enriched with cis-9,trans-11 conjugated linoleic acid on the blood lipid profile in healthy middle-aged men.
    Tricon S, Burdge GC, Jones EL, Russell JJ, El-Khazen S, Moretti E, Hall WL, Gerry AB, Leake DS, Grimble RF, Williams CM, Calder PC, Yaqoob P.
    Am J Clin Nutr. 2006 Apr;83(4):744-53.
    PMID: 16600923

    CONCLUSION: Dairy products naturally enriched with cis-9,trans-11 CLA and trans-11 18:1 do not appear to have a significant effect on the blood lipid profile
Matti Narkia

Long-term vitamin D3 supplementation may have adverse effects on serum lipids during po... - 0 views

  •  
    Long-term vitamin D3 supplementation may have adverse effects on serum lipids during postmenopausal hormone replacement therapy.
    Heikkinen AM, Tuppurainen MT, Niskanen L, Komulainen M, Penttilä I, Saarikoski S.
    Eur J Endocrinol. 1997 Nov;137(5):495-502.
    PMID: 9405029

    CONCLUSIONS: Our results confirm the positive long-term effect of HRT with sequential estradiol valerate and cyproterone acetate on serum lipid concentrations. In addition, the results suggest that vitamin D3 supplementation may have unfavorable effects on lipids in postmenopausal women. Pure vitamin D3 treatment was associated with increased serum LDL cholesterol. Furthermore, the beneficial effects of HRT on serum LDL cholesterol content were reduced when estradiol valerate was combined with vitamin D3. However, the relevance of these associations to cardiovascular morbidity remains to be established.
1 - 20 of 79 Next › Last »
Showing 20 items per page